Claims for Patent: 8,465,736

Summary for Patent: 8,465,736

Title:	Glutadon
Abstract:	The present invention relates to a pharmaceutical combination product for cancer therapy. The combination product comprises the two active ingredients glutaminase and 6-diazo-5-oxo-L-norleucine (DON). The invention further relates to the use of such a combination product for the treatment of cancers.
Inventor(s):	Bausch; Michael (Berlin, DE), Rainer; Wetzler (Berlin, DE), Muller; Christian (Berlin, DE)
Assignee:	New Medical Enzymes AG (Berlin, DE)
Application Number:	12/300,209
Patent Claims:	1. A combination product for cancer treatment, which combination product comprises the active ingredients a) glutaminase and b) 6-diazo-5-oxo-L-norleucine (DON), where active ingredient a) is present in a dosage of from 40 I.U./m.sup.2 to 300 I.U./m.sup.2 based on a recipient; and where active ingredient b) is present in a dosage of from 105 to 185 mg/m.sup.2 based on a recipient, where in the glutaminase is a glutaminase asparaginase from Pseudomonas 7A. 2. The combination product as claimed in claim 1, characterized in that active ingredient a) is modified and/or provided with one or more protective substances. 3. The combination product as claimed in claim 1, characterized in that active ingredient a) is present in a concentration of from 50 I.U./m.sup.2 to 200 I.U./m.sup.2 (international units per body surface area of recipient), based on a recipient, in the combination product. 4. The combination product as claimed in claim 1, characterized in that active ingredient a) is intended for administration three times a week to once every four weeks. 5. The combination product as claimed in claim 1, characterized in that active ingredient b) is intended for administration four times a week to once every two weeks. 6. The combination product as claimed in claim 1, characterized in that active ingredients a) and b) are present in a conjoint administration unit. 7. The combination product as claimed in claim 6, characterized in that active ingredients a) and b) are present in two separate administration units A) comprising active ingredient a) and B) comprising active ingredient b). 8. The combination product as claimed in claim 7, characterized in that at least one administration unit is in injectable form. 9. The combination product as claimed in claim 7, characterized in that at least one administration unit is in intravenous form. 10. The combination product as claimed in claim 7, characterized in that at least one administration unit is in oral form.

Details for Patent 8,465,736

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2026-05-10